As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable ...

Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as anti-tumor necrosis factor (TNF) agents, anti-integrin agents, interleukin ...

Hadlima is a tumor necrosis factor blocker indicated for appropriate patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ...

The word “tumor” is the last thing we want to hear.  After all, it immediately engenders feelings of uncertainty and anxiety.

ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated ...

The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...

In a recent case report, a novel immunophenotyping platform featuring high-parameter flow cytometry of peripheral blood mononuclear cells (PBMCs) enabled physicians to discover a unique skin disease ...